Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Despite insufficient data, writing panel will give recommendations for preparation, transfer, and follow-up for youth with ...

Reports Favorable National Health Strategies and Advancements in Glucose Monitoring Technologies Fuel Market Growth at a CAGR ...

Living with diabetes comes with a lot of risks and managing it can be both difficult and expensive. Chief Medical Officer for Abbott Diabetes Care Dr. Mahmood Kazemi and Medicare Beneficiary Fran List ...

The stakes are extremely high for the nearly 40 million Americans living with diabetes. This condition happens when the body doesn't produce enough insulin or i ...

Throughout it all, one of Abbott Laboratories' segments has been its best and most consistent growth driver: Diabetes care. Abbott Labs recently added a new product to this business that could ...

Priced at $49 for one 14-day sensor, or $89 per month, Abbott’s offering is competitive with Dexcom’s Stelo sensor.

Abbott has announced the U.S. availability of Lingo, the company’s first glucose monitoring system available without ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

Kiss a Pig Gala is the largest event in the state raising awareness and money for Diabetes research, advocacy and community ...